Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis
Obeticholic acid (OCA), the first FXR-targeting drug, has been claimed effective in the therapy of liver fibrosis. However, recent clinical trials indicated that OCA might not be effective against liver fibrosis, possibly due to the lower dosage to reduce the incidence of the side-effect of pruritus...
Main Authors: | Jiyu Zhou, Ningning Huang, Yitong Guo, Shuang Cui, Chaoliang Ge, Qingxian He, Xiaojie Pan, Guangji Wang, Hong Wang, Haiping Hao |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-05-01
|
Series: | Acta Pharmaceutica Sinica B |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2211383518304143 |
Similar Items
-
SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis
by: Jiyu Zhou, et al.
Published: (2020-01-01) -
Noncanonical farnesoid X receptor signaling inhibits apoptosis and impedes liver fibrosisResearch in context
by: Hong Wang, et al.
Published: (2018-11-01) -
Obeticholic acid-loaded exosomes attenuate liver fibrosis through dual targeting of the FXR signaling pathway and ECM remodeling
by: Arezou Azizsoltani, et al.
Published: (2023-12-01) -
Obeticholic Acid for Primary Biliary Cholangitis
by: Annarosa Floreani, et al.
Published: (2022-10-01) -
Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease
by: Ludovico Abenavoli, et al.
Published: (2018-10-01)